InflaRx (IFRX) director discloses sizeable share and option stakes

Rhea-AI Filing Summary

InflaRx N.V. director Nicolas Fulpius has filed an initial ownership report showing direct holdings of ordinary shares and stock options. He directly owns 490,052 ordinary shares. He also holds several stock option awards over ordinary shares with exercise prices between 1.17 and 2.41 per share and expiration dates running from late 2027 through early 2036. Footnotes state that most earlier option grants are already fully vested and exercisable, while an option granted on January 6, 2026 will vest in four equal quarterly installments of 11,250 shares, subject to continued service.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Fulpius Nicolas

(Last) (First) (Middle)

C/O INFLARX N.V.

WINZERLAER STREET 2

(Street)

JENA 07745

(City) (State) (Zip)

GERMANY

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
InflaRx N.V. [ IFRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	490,052	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	12/13/2027	Ordinary Shares	34,464	$1.86	D
Stock Option (Right to Buy)	(2)	01/04/2031	Ordinary Shares	30,000	$1.86	D
Stock Option (Right to Buy)	(3)	07/01/2031	Ordinary Shares	9,601	$1.86	D
Stock Option (Right to Buy)	(4)	01/11/2032	Ordinary Shares	45,000	$1.86	D
Stock Option (Right to Buy)	(5)	01/24/2033	Ordinary Shares	45,000	$2.37	D
Stock Option (Right to Buy)	(6)	01/05/2034	Ordinary Shares	45,000	$1.79	D
Stock Option (Right to Buy)	(7)	01/03/2035	Ordinary Shares	45,000	$2.41	D
Stock Option (Right to Buy)	(8)	01/06/2036	Ordinary Shares	45,000	$1.17	D

Explanation of Responses:

1. This option was granted on December 13, 2017 and is fully vested and exercisable as of the date hereof.

2. This option was granted on January 4, 2021 and is fully vested and exercisable as of the date hereof.

3. This option was granted on July 2, 2021 and is fully vested and exercisable as of the date hereof.

4. This option was granted on January 12, 2022 and is fully vested and exercisable as of the date hereof.

5. This option was granted on January 24, 2023 and is fully vested and exercisable as of the date hereof.

6. This option was granted on January 5, 2024 and is fully vested and exercisable as of the date hereof.

7. This option was granted on January 3, 2025 and is fully vested and exercisable as of the date hereof.

8. This option was granted on January 6, 2026 and will vest and become exercisable in four equal installments of 11,250 shares on each quarterly anniversary of such grant date, subject to continued service through such dates.

Remarks:

Exhibit List - Exhibit 24.1 Power of Attorney

	/s/ Christian Schmid, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does InflaRx (IFRX) director Nicolas Fulpius report owning on this Form 3?

Nicolas Fulpius reports direct ownership of 490,052 InflaRx ordinary shares, plus multiple stock option awards over additional ordinary shares. These options provide future rights to buy shares at fixed exercise prices, subject to their vesting schedules and expiration dates detailed in the filing.

What stock options does Nicolas Fulpius hold in InflaRx (IFRX)?

He holds several stock options over InflaRx ordinary shares, with exercise prices ranging from 1.17 to 2.41 per share. The options have staggered expiration dates between 2027 and 2036, providing long-dated rights to acquire additional equity if exercised.

Are Nicolas Fulpius’s InflaRx stock options vested and exercisable?

Footnotes state options granted in 2017, 2021, 2022, 2023, 2024, and 2025 are fully vested and exercisable. An option granted on January 6, 2026 will vest in four equal quarterly installments, subject to continued board service.

How does the January 6, 2026 InflaRx option for Nicolas Fulpius vest?

The January 6, 2026 option will vest and become exercisable in four equal installments of 11,250 shares on each quarterly anniversary of the grant date. Vesting is conditioned on continued service through those quarterly vesting dates, according to the footnote disclosure.

Does this InflaRx (IFRX) Form 3 show any recent insider share purchases or sales?

The Form 3 presents holdings rather than new transactions, and transaction records are coded as holdings with unknown direction. It lists existing ordinary share and option positions for Nicolas Fulpius, without identifying open-market purchases or sales during the reported period.